Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

In the Literature

  • Article

    Safety of Diltiazem in Patients Taking Apixaban or Rivaroxaban

    March 4, 2025

    Clinical question: Does diltiazem increase the risk of major bleeding in patients on apixaban or rivaroxaban? Background: Diltiazem is a potent CYP3A4 inhibitor and a mild P-glycoprotein inhibitor....

  • Article

    Semaglutide Decreases Risk of Kidney Failure, Worsening of Kidney Disease, and Kidney-Related or Cardiovascular Death

    March 4, 2025

    Clinical question: Does treatment with semaglutide in patients with chronic kidney disease (CKD) and diabetes mellitus (DM) type II reduce the risk of kidney failure, progression of chronic kidney...

  • Article

    Absence of CSF Pleocytosis Prevalent in Encephalitis and Can Delay Empiric Treatment

    March 4, 2025

    Clinical question: Is there a difference in clinical factors and outcomes among patients with new-onset encephalitis based on whether their initial cerebrospinal fluid (CSF) studies demonstrate the...

  • Article

    Efficacy of AI models in Detecting Clinical Deterioration

    January 1, 2025

    Clinical question: Can an artificial intelligence (AI) enabled intervention model reduce the risk of clinical deterioration and subsequent care escalation in hospitalized patients? Background:...

  • Article

    Metronidazole-Related Encephalopathy and Neuropathy Associated with IV Administration, Liver Cirrhosis, and CKD

    January 1, 2025

    Clinical question: What is the prevalence of metronidazole-related neurologic adverse events and what are the risk factors associated with these events? Background: A 2021 study reported neurologic...

  • Article

    Comparison of Hospital Mortality and Readmission Rates by Physician and Patient Sex

    January 1, 2025

    Clinical question: Are hospital mortality and readmission rates associated with physician sex, and do these associations vary by patient sex? Background: Prior studies indicate that physician...

  • Article

    Inhaled Amikacin in the First 72 Hours of Mechanical Ventilation Reduced the Incidence of VAP

    January 1, 2025

    Clinical question: Does inhaled amikacin reduce the incidence of ventilator-associated pneumonia (VAP) in critically ill patients? Background: VAP is a common and serious complication in patients on...

  • Article

    90-Day Mortality Among Septic Patients Given Piperacillin-Tazobactam Versus Cefepime

    January 1, 2025

    Clinical question: In patients with undifferentiated sepsis without an indication for anaerobic coverage, is there increased mortality with the combined use of vancomycin/piperacillin-tazobactam...

  • Article

    Hydrocortisone Plus Fludrocortisone for CAP-Related Septic Shock

    January 1, 2025

    Clinical question: Does hydrocortisone and fludrocortisone reduce all-cause mortality among patients with septic shock due to community-acquired pneumonia (CAP)? Background: A meta-analysis of 17...

  • Article

    Empagliflozin After Acute Myocardial Infarction (EMPACT-MI)

    January 1, 2025

    Clinical question: Does starting empagliflozin for patients with acute myocardial infarction (AMI) and new onset systolic heart failure (HF) or congestive symptoms reduce the risk of first...

Previous1 … 5 6 7 8 9 … 29Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences